Assessment of prognostic value and development of predictive model for prolonged lymphopenia in patients with glioblastoma following chemoradiotherapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prolonged lymphopenia after glioblastoma chemoradiotherapy is linked to shorter progression-free survival. Predictive factors include irradiated brain volume and patient characteristics, suggesting strategies to reduce radiation exposure may improve outcomes.
Area Of Science
- Neuro-oncology
- Radiation Oncology
- Immunology
Background
- Lymphopenia during chemoradiotherapy (CRT) for glioblastoma is a known poor prognostic factor.
- The impact of prolonged lymphopenia (PL) after CRT on glioblastoma prognosis requires further investigation.
Purpose Of The Study
- To investigate the association between PL and glioblastoma prognosis.
- To develop a predictive model for PL risk following CRT.
Main Methods
- Analysis of 87 primary glioblastoma patients undergoing postoperative CRT.
- Definition of PL as grade 2+ lymphopenia one month post-CRT.
- Survival analysis, risk factor identification, and predictive model development.
Main Results
- 41 out of 87 patients developed PL.
- PL was associated with significantly shorter progression-free survival (PFS) (8.0 vs 15.4 months).
- Brain V20Gy, gross total resection (GTR), and preoperative Karnofsky performance status (KPS) were significant risk factors for PL.
Conclusions
- Prolonged lymphopenia is a significant factor for shorter PFS in glioblastoma patients.
- A predictive model incorporating irradiated brain volume, GTR, and KPS can estimate PL risk.
- Reducing irradiated brain volume may prevent PL and potentially improve glioblastoma prognosis by preserving anti-tumor immunity.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.